GlassScriptPhysician profile
Leslie A Larson
NPI 1902249204
$3,394.38
in general payments reported to CMS, 2019-2025
25 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $498 · 2023: $793 · 2024: $904 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $588.30 | 2022-2025 | Aveir, Merlin@Home, Gallant |
| Novartis Pharmaceuticals Corporation | $403.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $313.91 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $311.82 | 2022-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $270.44 | 2021-2025 | Linq II, Micra, Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.02 | 2023-2025 | Lifevest |
| Amgen INC. | $233.97 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $204.46 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $186.51 | 2022-2025 | Farxiga, Andexxa |
| Abiomed | $95.97 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.55 | 2022-2024 | Jardiance |
| Inari Medical, INC. | $78.10 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $77.98 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Cvrx, INC. | $59.19 | 2022-2024 | Barostim Neo System |
| Pfizer INC. | $29.67 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.77 | 2025 | Injectafer |
| Baxter Healthcare | $26.14 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Surmodics, INC. | $24.82 | 2023 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter, Pounce Thrombectomy System |
| Regeneron Healthcare Solutions, INC. | $22.47 | 2025 | Evkeeza |
| United Therapeutics Corporation | $19.34 | 2025 | |
| Coala Life INC | $16.51 | 2021 | |
| Chiesi USA, INC. | $16.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.13 | 2025 | |
| Philips North America LLC | $16.07 | 2024 | (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $14.48 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.